2. Cell Cycle/DNA Damage Metabolic Enzyme/Protease Cytoskeleton
  3. Microtubule/Tubulin HIF/HIF Prolyl-Hydroxylase
  4. Cephalomannine

Cephalomannine is a Paclitaxel (HY-B0015) alkaloidal analog that can be isolated from most Cephalotaxus species. Cephalomannine is an orally active anti-tumor agent and can be used as a chemotherapy agent for cancer research.

For research use only. We do not sell to patients.

Cephalomannine Chemical Structure

Cephalomannine Chemical Structure

CAS No. : 71610-00-9

Size Price Stock Quantity
Solid + Solvent (Highly Recommended)
10 mM * 1 mL in DMSO
ready for reconstitution
 USD 198 In-stock
Solution
10 mM * 1 mL in DMSO USD 198 In-stock
Solid
1 mg USD 50 In-stock
5 mg USD 115 In-stock
10 mg USD 180 In-stock
50 mg   Get quote  
100 mg   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 1 publication(s) in Google Scholar

Other Forms of Cephalomannine:

Cephalomannine Related Antibodies

Top Publications Citing Use of Products

View All HIF/HIF Prolyl-Hydroxylase Isoform Specific Products:

View All Isoforms
HIF-1α HIF

  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

Cephalomannine is a Paclitaxel (HY-B0015) alkaloidal analog that can be isolated from most Cephalotaxus species. Cephalomannine is an orally active anti-tumor agent and can be used as a chemotherapy agent for cancer research[1][2][3][4].

IC50 & Target

HIF-1α

 

In Vitro

Cephalomannine significantly inhibits the proliferation of H460, A549 and H1299 cells under normal oxygen conditions, with IC50 values of 0.18, 0.20 and 0.37 μM, respectively. Cephalomannine shows obvious inhibitory effect on cell viability under hypoxia[3].
Cephalomannine (0, 0.025, 0.05, 0.1 μM; 0, 12, 24h) inhibiting the interaction of APEX1/HIF-1α can also significantly inhibit the cell viability, ROS production, intracellular pH, migration of hypoxic lung cancer cells, and angiogenesis of hypoxic human umbilical vein endothelial cells (HUVECs)[3].
Cephalomannine dose-dependently inhibits UBE2S expression and thus suppresses prostate cancer (PCa) growth and metastasis[4].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cephalomannine Related Antibodies

Cell Line:
Concentration:
Incubation Time:
Result:

RT-PCR[3]

Cell Line: H460 and A549 cell lines
Concentration: 0, 0.025, 0.05, 0.1 μM
Incubation Time: 0, 12, 24h
Result: After 24 h, the relative expression of APEX1 and HIF-1α was significantly inhibited.

Immunofluorescence[3]

Cell Line: H460 and A549 cell lines
Concentration: 0, 0.025, 0.05, 0.1 μM
Incubation Time: 0, 12, 24h
Result: HIF-1α levels were increased in hypoxic lung cancer cells.

Western Blot Analysis[3]

Cell Line: H460 and A549 cell lines
Concentration: 0, 0.025, 0.05, 0.1 μM
Incubation Time: 0, 12, 24h
Result: The expression of APEX1 and HIF-1α was decreased.
In Vivo

Cephalomannine (0.4 mg/kg, intraperitoneal injection, 10 days) could significantly inhibit the growth of lung cancer cells in nude mice xenograft model, with no obvious side effects[3].
Cephalomannine can interrupt the interaction between APEX1 and HIF-1α by competitive binding with APEX1[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: BALB/C nude mice xenograft model[3]
Dosage: 0.4 mg/kg
Administration: Intraperitoneal injection (i.p.)
Result: Reduced the volume and weight of H460 xenograft tumors.
Animal Model: BALB/c nude mice bone metastasis xenograft model[4]
Dosage: 10 mg/kg, 20 mg/kg
Administration: Intraperitoneal injection (i.p.)
Result: Decreased bone destruction, reduced bioluminescence intensity and number of bone metastases, significantly extended time to endpoint events, decreased UBE2S expression and number of osteoclasts, and did not produce significant toxicity to the heart, liver, or kidney of nude mice.
Molecular Weight

831.90

Formula

C45H53NO14
CAS No.
Appearance

Solid

Color

White to off-white

SMILES

O=C(/C(C)=C/C)N[C@@H](C1=CC=CC=C1)[C@H](C(O[C@@H]2C(C)=C([C@@H](OC(C)=O)C([C@@]3(C)[C@]([C@](OC(C)=O)(CO4)[C@H]4C[C@@H]3O)([H])[C@@H]5OC(C6=CC=CC=C6)=O)=O)C(C)(C)[C@@]5(O)C2)=O)O
Structure Classification
Initial Source
Shipping

Room temperature in continental US; may vary elsewhere.
Storage

4°C, protect from light

*In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

Solvent & Solubility
In Vitro: 

DMSO : ≥ 100 mg/mL (120.21 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

*"≥" means soluble, but saturation unknown.

Preparing
Stock Solutions
Concentration Solvent Mass 1 mg 5 mg 10 mg
1 mM 1.2021 mL 6.0103 mL 12.0207 mL
5 mM 0.2404 mL 1.2021 mL 2.4041 mL
View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

  • Molarity Calculator

  • Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass
=
Concentration
×
Volume
×
Molecular Weight *

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start)

C1

×
Volume (start)

V1

=
Concentration (final)

C2

×
Volume (final)

V2

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

  • Protocol 1

    Add each solvent one by one:  10% DMSO    40% PEG300    5% Tween-80    45% Saline

    Solubility: ≥ 2.5 mg/mL (3.01 mM); Clear solution

    This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

    Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

    Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
  • Protocol 2

    Add each solvent one by one:  10% DMSO    90% Corn Oil

    Solubility: ≥ 2.5 mg/mL (3.01 mM); Clear solution

    This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

    Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

g

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
%
DMSO +
% 
+
%
Tween-80 +
%
Saline
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Calculation results:
Working solution concentration: mg/mL
Method for preparing stock solution: mg drug dissolved in μL  DMSO (Stock solution concentration: mg/mL).

*In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).
Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.
 If the continuous dosing period exceeds half a month, please choose this protocol carefully.
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Purity & Documentation

Purity: 98.49%

COA (261 KB) LCMS (266 KB)

Handling Instructions (2659 KB)
References

Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Optional Solvent Concentration Solvent Mass 1 mg 5 mg 10 mg 25 mg
DMSO 1 mM 1.2021 mL 6.0103 mL 12.0207 mL 30.0517 mL
5 mM 0.2404 mL 1.2021 mL 2.4041 mL 6.0103 mL
10 mM 0.1202 mL 0.6010 mL 1.2021 mL 3.0052 mL
15 mM 0.0801 mL 0.4007 mL 0.8014 mL 2.0034 mL
20 mM 0.0601 mL 0.3005 mL 0.6010 mL 1.5026 mL
25 mM 0.0481 mL 0.2404 mL 0.4808 mL 1.2021 mL
30 mM 0.0401 mL 0.2003 mL 0.4007 mL 1.0017 mL
40 mM 0.0301 mL 0.1503 mL 0.3005 mL 0.7513 mL
50 mM 0.0240 mL 0.1202 mL 0.2404 mL 0.6010 mL
60 mM 0.0200 mL 0.1002 mL 0.2003 mL 0.5009 mL
80 mM 0.0150 mL 0.0751 mL 0.1503 mL 0.3756 mL
100 mM 0.0120 mL 0.0601 mL 0.1202 mL 0.3005 mL
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.

Cephalomannine Related Classifications

Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

Cephalomannine71610-00-9Microtubule/TubulinHIF/HIF Prolyl-HydroxylaseHypoxia-inducible factorsHIFsHIF-PHAnti-Tumoralkaloidal analogchemotherapyCephalotaxusprostate cancerInhibitorinhibitorinhibit

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

  

Salutation

Applicant Name *

 

Email Address *

Phone Number *

 

Organization Name *

Department *

 

Requested quantity *

Country or Region *

      

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
Cephalomannine
Cat. No.:
HY-77554
Quantity:
MCE Japan Authorized Agent:

Customer Review

Thank You for Your Feedback!

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

Product Name

  

Lot #

Applicant Name *

 

Email Address *

Phone Number

 

Department *

Organization Name *

 

Country or Region *

Remarks

Request for HNMR Report

We have received your request and will respond to you as soon as possible.